Stockreport

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitatio [Read more]